Prometheus BioScience Inc. Opens the French Part of Its Clinical Trial in Cell Therapy

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

http://www.biospace.com/news_story.aspx?StoryID=288906&full=1